CAMBRIDGE, Mass.--(BW HealthWire)--May 4, 2001--Alkermes, Inc. (NASDAQ: ALKS), announced today that its corporate presentation will be webcast live by the Deutsche Banc Alex. Brown 2001 Healthcare conference on Tuesday, May 8, 2001 at 5:30pm EST. Investors may access the webcast at http://www.db.com/conferences. A replay of the presentation will be available by the end of the day and will be archived for 14 days.
James Frates, Chief Financial Officer of Alkermes, Inc., will present an overview of the company at 5:30pm EST on Tuesday, May 8, 2001, from the Baltimore Marriott Waterfront Hotel in Baltimore, Maryland.
Alkermes is a leader in the development of products based on sophisticated drug delivery technologies. Its first product, Nutropin Depot(TM), is a long-acting form of Genentech's recombinant human growth hormone using Alkermes' ProLease(R) technology. The company has several areas of focus, including (i) controlled, sustained release of injectable drugs lasting several days to several weeks, utilizing its ProLease(R) and Medisorb(R) technologies and (ii) the development of pharmaceutical products based on proprietary pulmonary drug delivery technologies utilizing its AIR(TM) technology. In addition to its Cambridge, Massachusetts headquarters, research and manufacturing facilities, Alkermes operates research and manufacturing facilities in Ohio and a medical affairs office in Cambridge, England.
--30--dp/bos*
| CONTACT: | Alkermes, Inc. |
|---|---|
| Investor Relations | |
| Rebecca Peterson | |
| Director, Investor Relations | |
| (617) 583-6378 | |
| or | |
| Burns McClellan | |
| Media Relations | |
| Justin Jackson | |
| (212) 213-0006 | |